{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:13:22Z","timestamp":1746116002491,"version":"3.40.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.hpb.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T16:21:41Z","timestamp":1739809301000},"page":"716-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-7034","authenticated-orcid":false,"given":"Leonoor V.","family":"Wismans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory D.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-6725","authenticated-orcid":false,"given":"Casper W.F.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-3676","authenticated-orcid":false,"given":"Maaike","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine H.","family":"GeurtsvanKessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-2157","authenticated-orcid":false,"given":"Casper H.J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek A.","family":"van der Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2025.02.002_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19063731","article-title":"Quality of life in patients with pancreatic cancer before and during the COVID-19 pandemic","volume":"19","author":"Alexander","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.hpb.2025.02.002_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s43018-020-0074-y","article-title":"The impact of the COVID-19 pandemic on cancer care","volume":"1","author":"Richards","year":"2020","journal-title":"Nat Can (Ott)"},{"key":"10.1016\/j.hpb.2025.02.002_bib3","article-title":"The COVID-19 pandemic is associated with reduced survival after pancreatic ductal adenocarcinoma diagnosis: a single-centre retrospective analysis","volume":"11","author":"Madge","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.hpb.2025.02.002_bib4","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41416-023-02220-2","article-title":"The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study","volume":"128","author":"Hall","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184621","article-title":"Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVer study): a prospective cohort study of the hellenic cooperative oncology group","volume":"13","author":"Linardou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.hpb.2025.02.002_bib7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.hpb.2022.03.002","article-title":"Collaborative CO. Outcomes of patients undergoing elective liver and pancreas cancer surgery during the SARS-CoV-2 pandemic: an international, multicentre, prospective cohort study","volume":"24","author":"McKay","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.hpb.2025.02.002_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.hpb.2025.02.002_bib9","series-title":"Cancer statistics","first-page":"1542","author":"Siegel","year":"2020"},{"key":"10.1016\/j.hpb.2025.02.002_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/SLA.0000000000005865","article-title":"Increasing systemic immune-inflammation index during treatment in patients with advanced pancreatic cancer is associated with poor survival: a retrospective, multicenter, cohort study","volume":"278","author":"van 't Land","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.02.002_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/SLA.0000000000002660","article-title":"The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study","volume":"270","author":"Aziz","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.02.002_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ctrv.2013.11.005","article-title":"Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies","volume":"40","author":"Sideras","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hpb.2025.02.002_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib15","article-title":"Difference in immunogenic responses to COVID-19 vaccines in patients with cancer receiving chemotherapy versus nonchemotherapy treatment","volume":"9","author":"Tantiyavarong","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib16","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.21037\/jgo-22-1065","article-title":"Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?","volume":"14","author":"Monin","year":"2023","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s00432-022-04185-w","article-title":"Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis","volume":"149","author":"Martins-Branco","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2022.05.029","article-title":"Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis","volume":"172","author":"Mai","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113440","article-title":"FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: implications for combination therapies and early response prediction","volume":"196","author":"van Eijck","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00262-004-0638-1","article-title":"Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas","volume":"54","author":"Plate","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.hpb.2025.02.002_bib21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.hpb.2025.02.002_bib23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hpb.2025.02.002_bib24","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/annonc\/mdq728","article-title":"Response to influenza virus vaccination during chemotherapy in patients with breast cancer","volume":"22","author":"Meerveld-Eggink","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol."},{"key":"10.1016\/j.hpb.2025.02.002_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1515\/cclm-2021-0023","article-title":"Evaluation of the automated LIAISON(\u00ae) SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies","volume":"59","author":"Bonelli","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.hpb.2025.02.002_bib27","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/s41416-022-01951-y","article-title":"Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review","volume":"127","author":"Al Hajji","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1470-2045(22)00203-0","article-title":"Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours","volume":"23","author":"Oosting","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2025.02.002_bib29","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hpb.2025.02.002_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","article-title":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article","volume":"162","author":"Barri\u00e8re","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.02.002_bib32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/oncolo\/oyac230","article-title":"SARS-CoV-2 vaccine immunogenicity in patients with gastrointestinal cancer receiving systemic anti-cancer therapy","volume":"28","author":"Lau","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.hpb.2025.02.002_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11101615","article-title":"Factors affecting SARS-CoV-2 IgG production after vaccination and\/or disease: a large-scale seroprevalence study","volume":"11","author":"Karl","year":"2023","journal-title":"Vaccines"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T09:13:14Z","timestamp":1746004394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X25000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1365182X25000619"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2025.02.002","relation":{},"ISSN":["1365-182X"],"issn-type":[{"type":"print","value":"1365-182X"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc.","name":"copyright","label":"Copyright"}]}}